Plaque Psoriasis
Conditions
Brief summary
Sixteen week open label study of apremilast in combination with topical steroids with a four week safety follow up visit.
Detailed description
This is an open label, 16 week study of apremilast in combination with topical corticosteroids (TCS). Twenty qualified subjects will be enrolled. Visits will consist of Baseline, 8 week, 16 week and a 20 week safety follow up after 4 weeks off treatment. Subjects will dose with apremilast as per label. Topical corticosteroids (TCS) will be used for up to Week 4 as per label and then will be used on an as needed basis until Week 16. Assessments will include Static Physicians Global Assessment (sPGA), Psoriasis Area Severity Index (PASI), Psoriatic Body Surface Area (BSA), Dermatology Life Quality Index (DLQI),Assessment of Pruritus, Patient Satisfaction questionnaire. and Patient Global Assessment (PtGA)
Interventions
DRUGApremilast
Sponsors
Celgene
Derm Research, PLLC
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subjects must be in general good health as judged by investigator * Female of childbearing potential (FCBP) must have a negative pregnancy test at screening and Baseline. * FCBP must use an approved method of contraception as outlined in the protocol. * Male subjects who engage in activity in which conception is possible must use barrier contraception as defined in the protocol. * 18 years of age or older * Understand and voluntarily sign the Informed Consent * Able to adhere to study visit schedule * Moderate plaque type psoriasis as define by a a PGA of 3 * BSA 0f 5-10% or a DLQI score of 7 or more * History of uncontrolled plaque psoriasis after either stable dose of high potency topical steroids for 2 weeks or mid-potency steroids for 4 weeks within the last 6 months
Exclusion criteria
* Any clinically significant disease as determined by the investigator or major disease that is currently uncontrolled * Any condition, including the presence of laboratory abnormalities, which would place the subject at unacceptable risk * Prior history of suicide attempt at any time in the subject's lifetime prior to screening or randomization, or major psychiatric illness requiring hospitalization within the last 3 years * Pregnant or breastfeeding, FCBP who are not willing to use acceptable birth control methods. * Active substance abuse or a history of substance abuse within 6 months prior to screening. * Malignancy or history of malignancy except fo treated (cured) basal cell or or squamous cell in situ skin carcinomas, treated (cured) cervical intraepithelial neoplasia or carcinoma in situ of the cervix with no evidence of recurrence within the previous 5 years * Has not completed the prescribed washout for restricted treatments * Known or suspected allergy to investigational product * Other types of psoriasis * Prior history of depression * Prior use of apremilast
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean Change in Product of BSA (Body Surface Affected by Psoriasis) and sPGA (Static Physician Global Assessment) From Baseline to Week 16 | Week 16 | The area of body surface affected by psoriasis (BSA) will be estimated by the Investigator as a percentage of the subject's total body surface area wherein the area of the subject's palm will be considered as 1% of total BSA. Static Physician Global Assessment (sPGA) of disease severity is measured by the Investigator on a 6-point scale wherein 0=Clear, 1=Almost Clear, 2=Mild, 3=Moderate, 4=Severe, 5=Very Severe. The product of these values offers a more specific assessment of the severity of psoriasis. This product can yield a result between 0 (no disease) and 500 (most severe disease) By reporting the percent change as well as the absolute value change, the reader may be better able to appreciate the impact on disease severity of the medication under study. |
| Percent Change in Product of BSA and sPGA | Week 16 | The area of body surface affected by psoriasis (BSA) will be estimated by the Investigator as a percentage of the subject's total body surface area wherein the area of the subject's palm will be considered as 1% of total BSA. Static Physician Global Assessment (sPGA) is measured by the Investigator on a 6-point scale wherein 0=Clear, 1=Almost Clear, 2=Mild, 3=Moderate, 4=Severe, 5=Very Severe. The product of these values offers a more specific assessment of the severity of psoriasis. This product can yield a result between 0(no disease) and 500 (most severe disease.) By reporting the percent change as well as the absolute value change, the reader may be better able to appreciate the impact on disease severity of the medication under study. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percent Change in Product of BSA and sPGA | Week 8 | The area of body surface affected by psoriasis (BSA) will be estimated by the Investigator as a percentage of the subject's total body surface area wherein the area of the subject's palm will be considered as 1% of total BSA. Static Physician Global Assessment (sPGA) is measured by the Investigator on a 6-point scale wherein 0=Clear, 1=Almost Clear, 2=Mild, 3=Moderate, 4=Severe, 5=Very Severe. Th3 product of these values offers a more specific assessment of the severity of psoriasis. This product may yield a result between 0 (no disease) and 500 (most severe disease.) |
| Mean Change in DLQI | Week 8 | The Dermatology Life Quality Index (DLQI) is a 10-question survey administered to subjects in order to ascertain the extent to which psoriasis has affected the patient's life in the week prior to completing the questionnaire. The score is a sum of the value of each answer wherein Very Much=3, A lot=2, A little=1 and Not at all=0. 0 is the lowest possible score and indicates no impact of disease on quality of life. 30 is the highest possible score and indicates the most negative impact of disease on quality of life. |
| Mean Change in Pruritus Scores | Baseline to Week 8 | The Subject Assessments of pruritis is measured at screening, baseline, and weeks 4, 8 and 16. Each subject rates the severity of their itching over the last 24 hours on a 10-point scale from 0 (none) to 10 (unbearable) |
| Mean Change in BSA | Baseline to Week 8 | The area of body surface affected by psoriasis (BSA) will be estimated by the Investigator as a percentage of the subject's total body surface area wherein the area of the subject's palm will be considered as 1% of total BSA. This will be assessed at screening, baseline, and weeks 4, 8 and 16 |
| Percent Change in BSA | Baseline to Week 8 | The area of body surface affected by psoriasis (BSA) will be estimated by the Investigator as a percentage of the subject's total body surface area wherein the area of the subject's palm will be considered as 1% of total BSA. This will be assessed at screening, baseline, and weeks 4, 8 and 16 |
| Proportion of Patients Who Achieve PASI 50 | Week 8 | The Psoriasis Area Severity index (PASI) is performed at screening, baseline, and weeks 4, 8 and 16. This tool is used to measure the severity and extent of disease by combining the assessment of severity of lesions and the area affected into a single score in the range of 0 (no disease) to 72 (maximal disease.) |
| Proportion of Patients Who Achieve PASI 75 | Week 8 | The Psoriasis Area Severity index (PASI) is performed at screening, baseline, and weeks 4, 8 and 16. This tool is used to measure the severity and extent of disease by combining the assessment of severity of lesions and the area affected into a single score in the range of 0 (no disease) to 72 (maximal disease.) |
| % of Patients Achieving Clear or Almost Clear on the PtGA | Week 8 | The Psoriasis Area Severity index (PASI) is performed at screening, baseline, and weeks 4, 8 and 16. This tool is used to measure the severity and extent of disease by combining the assessment of severity of lesions and the area affected into a single score in the range of 0 (no disease) to 72 (maximal disease.) |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Apremilast Apremilast, 30 mg. tablets, two times a day for 16 weeks
Apremilast | 20 |
| Total | 20 |
Baseline characteristics
| Characteristic | Apremilast |
|---|---|
| Age, Continuous | 55 years STANDARD_DEVIATION 14 |
| Race/Ethnicity, Customized black | 2 Participants |
| Race/Ethnicity, Customized white | 18 Participants |
| Region of Enrollment United States | 20 participants |
| Sex: Female, Male Female | 5 Participants |
| Sex: Female, Male Male | 15 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 20 |
| other Total, other adverse events | 17 / 20 |
| serious Total, serious adverse events | 0 / 20 |
Outcome results
Primary
Mean Change in Product of BSA (Body Surface Affected by Psoriasis) and sPGA (Static Physician Global Assessment) From Baseline to Week 16
The area of body surface affected by psoriasis (BSA) will be estimated by the Investigator as a percentage of the subject's total body surface area wherein the area of the subject's palm will be considered as 1% of total BSA. Static Physician Global Assessment (sPGA) of disease severity is measured by the Investigator on a 6-point scale wherein 0=Clear, 1=Almost Clear, 2=Mild, 3=Moderate, 4=Severe, 5=Very Severe. The product of these values offers a more specific assessment of the severity of psoriasis. This product can yield a result between 0 (no disease) and 500 (most severe disease) By reporting the percent change as well as the absolute value change, the reader may be better able to appreciate the impact on disease severity of the medication under study.
Time frame: Week 16
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Apremilast | Mean Change in Product of BSA (Body Surface Affected by Psoriasis) and sPGA (Static Physician Global Assessment) From Baseline to Week 16 | -9 score on a scale | Standard Deviation 10 |
Primary
Percent Change in Product of BSA and sPGA
The area of body surface affected by psoriasis (BSA) will be estimated by the Investigator as a percentage of the subject's total body surface area wherein the area of the subject's palm will be considered as 1% of total BSA. Static Physician Global Assessment (sPGA) is measured by the Investigator on a 6-point scale wherein 0=Clear, 1=Almost Clear, 2=Mild, 3=Moderate, 4=Severe, 5=Very Severe. The product of these values offers a more specific assessment of the severity of psoriasis. This product can yield a result between 0(no disease) and 500 (most severe disease.) By reporting the percent change as well as the absolute value change, the reader may be better able to appreciate the impact on disease severity of the medication under study.
Time frame: Week 16
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Apremilast | Percent Change in Product of BSA and sPGA | -44 percent change | Standard Deviation 52 |
Secondary
Mean Change in BSA
The area of body surface affected by psoriasis (BSA) will be estimated by the Investigator as a percentage of the subject's total body surface area wherein the area of the subject's palm will be considered as 1% of total BSA. This will be assessed at screening, baseline, and weeks 4, 8 and 16
Time frame: Week 16
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Apremilast | Mean Change in BSA | -2 percentage of body surface area affected | Standard Deviation 3 |
Secondary
Mean Change in BSA
The area of body surface affected by psoriasis (BSA) will be estimated by the Investigator as a percentage of the subject's total body surface area wherein the area of the subject's palm will be considered as 1% of total BSA. This will be assessed at screening, baseline, and weeks 4, 8 and 16
Time frame: Baseline to Week 8
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Apremilast | Mean Change in BSA | -1 percentage of body surface area affected | Standard Deviation 2 |
Secondary
Mean Change in DLQI
The Dermatology Life Quality Index (DLQI) is a 10-question survey administered to subjects in order to ascertain the extent to which psoriasis has affected the patient's life in the week prior to completing the questionnaire. The score is a sum of the value of each answer wherein Very Much=3, A lot=2, A little=1 and Not at all=0. 0 is the lowest possible score and indicates no impact of disease on quality of life. 30 is the highest possible score and indicates the most negative impact of disease on quality of life.
Time frame: Week 16
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Apremilast | Mean Change in DLQI | -7 units on a scale | Standard Deviation 5 |
Secondary
Mean Change in DLQI
The Dermatology Life Quality Index (DLQI) is a 10-question survey administered to subjects in order to ascertain the extent to which psoriasis has affected the patient's life in the week prior to completing the questionnaire. The score is a sum of the value of each answer wherein Very Much=3, A lot=2, A little=1 and Not at all=0. 0 is the lowest possible score and indicates no impact of disease on quality of life. 30 is the highest possible score and indicates the most negative impact of disease on quality of life.
Time frame: Week 8
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Apremilast | Mean Change in DLQI | -6 score on a scale | Standard Deviation 5 |
Secondary
Mean Change in Pruritus Scores
The Subject Assessments of pruritis is measured at screening, baseline, and weeks 4, 8 and 16. Each subject rates the severity of their itching over the last 24 hours on a 10-point scale from 0 (none) to 10 (unbearable)
Time frame: Baseline to Week 16
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Apremilast | Mean Change in Pruritus Scores | -3 units on a scale | Standard Deviation 3 |
Secondary
Mean Change in Pruritus Scores
The Subject Assessments of pruritis is measured at screening, baseline, and weeks 4, 8 and 16. Each subject rates the severity of their itching over the last 24 hours on a 10-point scale from 0 (none) to 10 (unbearable)
Time frame: Baseline to Week 8
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Apremilast | Mean Change in Pruritus Scores | -3 units on a scale | Standard Deviation 2 |
Secondary
% of Patients Achieving Clear or Almost Clear on the PtGA
The Psoriasis Area Severity index (PASI) is performed at screening, baseline, and weeks 4, 8 and 16. This tool is used to measure the severity and extent of disease by combining the assessment of severity of lesions and the area affected into a single score in the range of 0 (no disease) to 72 (maximal disease.)
Time frame: Week 8
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Apremilast | % of Patients Achieving Clear or Almost Clear on the PtGA | 10 Participants |
Secondary
% of Patients Achieving Clear or Almost Clear on the PtGA
The Psoriasis Area Severity index (PASI) is performed at screening, baseline, and weeks 4, 8 and 16. This tool is used to measure the severity and extent of disease by combining the assessment of severity of lesions and the area affected into a single score in the range of 0 (no disease) to 72 (maximal disease.)
Time frame: Week 16
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Apremilast | % of Patients Achieving Clear or Almost Clear on the PtGA | 9 Participants |
Secondary
Percent Change in BSA
The area of body surface affected by psoriasis (BSA) will be estimated by the Investigator as a percentage of the subject's total body surface area wherein the area of the subject's palm will be considered as 1% of total BSA. This will be assessed at screening, baseline, and weeks 4, 8 and 16
Time frame: Baseline to Week 8
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Apremilast | Percent Change in BSA | -19 percent change | Standard Deviation 28 |
Secondary
Percent Change in BSA
The area of body surface affected by psoriasis (BSA) will be estimated by the Investigator as a percentage of the subject's total body surface area wherein the area of the subject's palm will be considered as 1% of total BSA. This will be assessed at screening, baseline, and weeks 4, 8 and 16
Time frame: Baseline to Week 16
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Apremilast | Percent Change in BSA | -36 percent change | Standard Deviation 49 |
Secondary
Percent Change in Product of BSA and sPGA
The area of body surface affected by psoriasis (BSA) will be estimated by the Investigator as a percentage of the subject's total body surface area wherein the area of the subject's palm will be considered as 1% of total BSA. Static Physician Global Assessment (sPGA) is measured by the Investigator on a 6-point scale wherein 0=Clear, 1=Almost Clear, 2=Mild, 3=Moderate, 4=Severe, 5=Very Severe. Th3 product of these values offers a more specific assessment of the severity of psoriasis. This product may yield a result between 0 (no disease) and 500 (most severe disease.)
Time frame: Week 8
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Apremilast | Percent Change in Product of BSA and sPGA | -29 percent change | Standard Deviation 36 |
Secondary
Proportion of Patients Who Achieve PASI 50
The Psoriasis Area Severity index (PASI) is performed at screening, baseline, and weeks 4, 8 and 16. This tool is used to measure the severity and extent of disease by combining the assessment of severity of lesions and the area affected into a single score in the range of 0 (no disease) to 72 (maximal disease.)
Time frame: Week 16
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Apremilast | Proportion of Patients Who Achieve PASI 50 | 8 Participants |
Secondary
Proportion of Patients Who Achieve PASI 50
The Psoriasis Area Severity index (PASI) is performed at screening, baseline, and weeks 4, 8 and 16. This tool is used to measure the severity and extent of disease by combining the assessment of severity of lesions and the area affected into a single score in the range of 0 (no disease) to 72 (maximal disease.)
Time frame: Week 8
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Apremilast | Proportion of Patients Who Achieve PASI 50 | 3 Participants |
Secondary
Proportion of Patients Who Achieve PASI 75
The Psoriasis Area Severity index (PASI) is performed at screening, baseline, and weeks 4, 8 and 16. This tool is used to measure the severity and extent of disease by combining the assessment of severity of lesions and the area affected into a single score in the range of 0 (no disease) to 72 (maximal disease.)
Time frame: Week 8
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Apremilast | Proportion of Patients Who Achieve PASI 75 | 0 Participants |
Secondary
Proportion of Patients Who Achieve PASI 75
The Psoriasis Area Severity index (PASI) is performed at screening, baseline, and weeks 4, 8 and 16. This tool is used to measure the severity and extent of disease by combining the assessment of severity of lesions and the area affected into a single score in the range of 0 (no disease) to 72 (maximal disease.)
Time frame: Week 16
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Apremilast | Proportion of Patients Who Achieve PASI 75 | 6 Participants |